Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 275-283

  Côte, Anik L ^a   Zhang, Peisheng ^a   O'Sullivan, Jeremy A ^b   Jacobs, Valerie L ^a   Clemis, Carli R ^a   Sakaguchi, Shimon ^c   Guevara Patiño, José A ^b   Jo Turk, Mary ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CD8 ANTIBODY; CYTOKINE RECEPTOR AFFECTING AGENT; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DTA 1; NK1.1 ANTIBODY; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CANCER GROWTH; CANCER SURGERY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOSTIMULATION; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR REJECTION; VITILIGO;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 79251553417     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001308     Document Type: Article

References (44)

1. Wood, L. D., D. W. Parsons, S. Jones, J. Lin, T. Sjöblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318: 1108-1113.
2. Monach, P. A., S. C. Meredith, C. T. Siegel, and H. Schreiber. 1995. A unique tumor antigen produced by a single amino acid substitution. Immunity 2: 45-59.
3. Neller, M. A., J. A. López, and C. W. Schmidt. 2008. Antigens for cancer immunotherapy. Semin. Immunol. 20: 286-295.
4. Duan, F., Y. Lin, C. Liu, M. E. Engelhorn, A. D. Cohen, M. Curran, S. Sakaguchi, T. Merghoub, S. Terzulli, J. D. Wolchok, and A. N. Houghton. 2009. Immune rejection of mouse tumors expressing mutated self. Cancer Res. 69: 3545-3553.
5. Prehn, R. T., and J. M. Main. 1957. Immunity to methylcholanthrene- induced sarcomas. J. Natl. Cancer Inst. 18: 769-778.
6. Schietinger, A., M. Philip, and H. Schreiber. 2008. Specificity in cancer immunotherapy. Semin. Immunol. 20: 276-285.
7. Uchi, H., R. Stan, M. J. Turk, M. E. Engelhorn, G. A. Rizzuto, S. M. Goldberg, J. D. Wolchok, and A. N. Houghton. 2006. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv. Immunol. 90: 215-241.
8. Attia, P., G. Q. Phan, A. V. Maker, M. R. Robinson, M. M. Quezado, J. C. Yang, R. M. Sherry, S. L. Topalian, U. S. Kammula, R. E. Royal, et al. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23: 6043-6053.
9. Maker, A. V., G. Q. Phan, P. Attia, J. C. Yang, R. M. Sherry, S. L. Topalian, U. S. Kammula, R. E. Royal, L. R. Haworth, C. Levy, et al. 2005. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12: 1005-1016.
10. + cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J. Immunol. 183: 7631-7634.
11. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3: 135-142.
12. Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68.
13. + regulatory T cells. J. Exp. Med. 202: 885-891.
14. Turk, M. J., J. A. Guevara-Patiño, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
15. Ramirez-Montagut, T., A. Chow, D. Hirschhorn-Cymerman, T. H. Terwey, A. A. Kochman, S. Lu, R. C. Miles, S. Sakaguchi, A. N. Houghton, and M. R. van den Brink. 2006. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 176: 6434-6442.
16. Cohen, A. D., D. A. Schaer, C. Liu, Y. Li, D. Hirschhorn-Cymmerman, S. C. Kim, A. Diab, G. Rizzuto, F. Duan, M. A. Perales, et al. 2010. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5: e10436.
17. + T cells. J. Immunol. 172: 7306-7314.
18. Ronchetti, S., O. Zollo, S. Bruscoli, M. Agostini, R. Bianchini, G. Nocentini, E. Ayroldi, and C. Riccardi. 2004. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur. J. Immunol. 34: 613-622.
19. + T cells. J. Immunol. 173: 5008-5020.
20. Zhang, P., A. L. Côté, V. C. de Vries, E. J. Usherwood, and M. J. Turk. 2007. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res. 67: 6468-6476.
21. + T-cell responses and tumor immunity. Cancer Res. 66: 4904-4912.
22. + T cell activation and experimental autoimmune encephalomyelitis. J. Immunol. 172: 4686-4690.
23. Patel, M., D. Xu, P. Kewin, B. Choo-Kang, C. McSharry, N. C. Thomson, and F. Y. Liew. 2005. Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis. Eur. J. Immunol. 35: 3581-3590.
24. Scheibenbogen, C., K. H. Lee, S. Stevanovic, M. Witzens, M. Willhauck, V. Waldmann, H. Naeher, H. G. Rammensee, and U. Keilholz. 1997. Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELISPOT assay. Int. J. Cancer 71: 932-936.
25. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188: 277-286.
26. + T cells. J. Immunol. 179: 5916-5926.
27. Ko, H. J., Y. J. Kim, Y. S. Kim, W. S. Chang, S. Y. Ko, S. Y. Chang, S. Sakaguchi, and C. Y. Kang. 2007. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67: 7477-7486.
28. + T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 68: 5948-5954.
29. Sharma, S., A. L. Dominguez, S. Z. Manrique, F. Cavallo, S. Sakaguchi, and J. Lustgarten. 2008. Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res. 68: 7530-7540.
30. Piao, J., Y. Kamimura, H. Iwai, Y. Cao, K. Kikuchi, M. Hashiguchi, T. Masunaga, H. Jiang, K. Tamura, S. Sakaguchi, and M. Azuma. 2009. Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. Immunology 127: 489-499.
31. Boczkowski, D., J. Lee, S. Pruitt, and S. Nair. 2009. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther. 209: 900-911.
32. Egen, J. G., and J. P. Allison. 2002. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16: 23-35.
33. Gregor, P. D., J. D. Wolchok, C. R. Ferrone, H. Buchinshky, J. A. Guevara- Patiño, M. A. Perales, F. Mortazavi, D. Bacich, W. Heston, J. B. Latouche, et al. 2004. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine 22: 1700-1708.
34. Hodge, J. W., M. Chakraborty, C. Kudo-Saito, C. T. Garnett, and J. Schlom. 2005. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174: 5994-6004.
35. Mitsui, J., H. Nishikawa, D. Muraoka, L. Wang, T. Noguchi, E. Sato, S. Kondo, J. P. Allison, S. Sakaguchi, L. J. Old, et al. 2010. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/ inhibitory signals. Clin. Cancer Res. 16: 2781-2791.
36. Nocentini, G., S. Ronchetti, S. Cuzzocrea, and C. Riccardi. 2007. GITR/GITRL: more than an effector T cell co-stimulatory system. Eur. J. Immunol. 37: 1165-1169.
37. Chen, S., L. C. Ndhlovu, T. Takahashi, K. Takeda, Y. Ikarashi, T. Kikuchi, K. Murata, P. P. Pandolfi, C. Riccardi, M. Ono, et al. 2008. Co-inhibitory roles for glucocorticoid-induced TNF receptor in CD1d-dependent natural killer T cells. Eur. J. Immunol. 38: 2229-2240.
38. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J. Immunol. 179: 7365-7375.
39. + T cells in vivo. J. Immunol. 182: 7490-7500.
40. + T-cell transfer in combination with in vivo GITR ligation. Mol. Ther. 17: 1274-1281.
41. Coe, D., S. Begom, C. Addey, M. White, J. Dyson, and J. G. Chai. 2010. Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol. Immunother. 59: 1367-1377.
42. + regulatory T cells. J. Leukoc. Biol. 82: 93-105.
43. Baltz, K. M., M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S. Kupka, et al. 2007. Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21: 2442-2454.
44. Baltz, K. M., M. Krusch, T. Baessler, B. J. Schmiedel, A. Bringmann, P. Brossart, and H. R. Salih. 2008. Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood 112: 3735-3743.